001     891058
005     20240701202016.0
024 7 _ |a 10.3390/molecules26061590
|2 doi
024 7 _ |a 2128/27418
|2 Handle
024 7 _ |a 33805709
|2 pmid
024 7 _ |a WOS:000645434200001
|2 WOS
024 7 _ |a altmetric:103579575
|2 altmetric
037 _ _ |a FZJ-2021-01341
082 _ _ |a 540
100 1 _ |a Post, Julia
|0 P:(DE-Juel1)164337
|b 0
245 _ _ |a A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model
260 _ _ |a Basel
|c 2021
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1719815346_15234
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterised by selective neuronal death in the brain stem and spinal cord. The cause is unknown, but an increasing amount of evidence has firmly certified that neuroinflammation plays a key role in ALS pathogenesis. Neuroinflammation is a pathological hallmark of several neurodegenerative disorders and has been implicated as driver of disease progression. Here, we describe a treatment study demonstrating the therapeutic potential of a tandem version of the well-known all-d-peptide RD2 (RD2RD2) in a transgenic mouse model of ALS (SOD1*G93A). Mice were treated intraperitoneally for four weeks with RD2RD2 vs. placebo. SOD1*G93A mice were tested longitudinally during treatment in various behavioural and motor coordination tests. Brain and spinal cord samples were investigated immunohistochemically for gliosis and neurodegeneration. RD2RD2 treatment in SOD1*G93A mice resulted not only in a reduction of activated astrocytes and microglia in both the brain stem and lumbar spinal cord, but also in a rescue of neurons in the motor cortex. RD2RD2 treatment was able to slow progression of the disease phenotype, especially the motor deficits, to an extent that during the four weeks treatment duration, no significant progression was observed in any of the motor experiments. Based on the presented results, we conclude that RD2RD2 is a potential therapeutic candidate against ALS.
536 _ _ |a 525 - Decoding Brain Organization and Dysfunction (POF4-525)
|0 G:(DE-HGF)POF4-525
|c POF4-525
|f POF IV
|x 0
536 _ _ |a 5244 - Information Processing in Neuronal Networks (POF4-524)
|0 G:(DE-HGF)POF4-5244
|c POF4-524
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Kogel, Vanessa
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Schaffrath, Anja
|0 P:(DE-Juel1)176527
|b 2
700 1 _ |a Lohmann, Philipp
|0 P:(DE-Juel1)145110
|b 3
700 1 _ |a Shah, N. J.
|0 P:(DE-Juel1)131794
|b 4
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 5
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 6
700 1 _ |a Willuweit, Antje
|0 P:(DE-Juel1)144347
|b 7
700 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 8
|e Corresponding author
773 _ _ |a 10.3390/molecules26061590
|g Vol. 26, no. 6, p. 1590 -
|0 PERI:(DE-600)2008644-1
|n 6
|p 1590 -
|t Molecules
|v 26
|y 2021
|x 1420-3049
856 4 _ |u https://juser.fz-juelich.de/record/891058/files/Invoice_MDPI_molecules-1102502.pdf
856 4 _ |u https://juser.fz-juelich.de/record/891058/files/molecules-26-01590.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:891058
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)164337
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)176527
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)145110
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)131794
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)131777
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)132029
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)144347
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)159137
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|x 0
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-524
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Molecular and Cellular Information Processing
|9 G:(DE-HGF)POF4-5244
|x 1
913 0 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-500
|4 G:(DE-HGF)POF
|v Neuroimaging
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-26
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2020-08-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOLECULES : 2018
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-08-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-08-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-08-26
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2020-08-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-08-26
920 1 _ |0 I:(DE-Juel1)IBI-7-20200312
|k IBI-7
|l Strukturbiochemie
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
920 1 _ |0 I:(DE-Juel1)INM-11-20170113
|k INM-11
|l Jara-Institut Quantum Information
|x 2
920 1 _ |0 I:(DE-Juel1)VDB1046
|k JARA-BRAIN
|l Jülich-Aachen Research Alliance - Translational Brain Medicine
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)IBI-7-20200312
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a I:(DE-Juel1)INM-11-20170113
980 _ _ |a I:(DE-Juel1)VDB1046
980 _ _ |a APC
980 _ _ |a UNRESTRICTED
980 1 _ |a APC
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21